Ticker
ACET

Price
1.69
Stock movement down
-0.09 (-5.06%)
Company name
Adicet Bio Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
72.59M
Ent value
-146.71M
Price/Sales
2.90
Price/Book
0.25
Div yield
2.37%
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-88.53%
3 year return
-50.58%
5 year return
-54.34%
10 year return
-
Last updated: 2023-09-08
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
August 9, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
June 27, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACET does not pay dividends or no data was received
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.90
Price to Book0.25
EV to Sales-5.87
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
June 27, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
June 26, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count42.95M
EPS (TTM)-2.14
FCF per share (TTM)-1.89

Income statement

Loading...
Income statement data
Revenue (TTM)24.99M
Gross profit (TTM)0.00
Operating income (TTM)-90.55M
Net income (TTM)-87.71M
EPS (TTM)-2.14
EPS (1y forward)-1.99

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-362.35%
Profit margin (TTM)-350.98%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash257.66M
Net receivables0.00
Total current assets261.04M
Goodwill19.46M
Intangible assets0.00
Property, plant and equipment0.00
Total assets330.69M
Accounts payable4.40M
Short/Current long term debt21.02M
Total current liabilities19.71M
Total liabilities38.35M
Shareholder's equity292.34M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-55.37M
Capital expenditures (TTM)22.26M
Free cash flow (TTM)-77.63M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-30.00%
Return on Assets-26.52%
Return on Invested Capital-29.75%
Cash Return on Invested Capital-26.33%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.79
Daily high1.80
Daily low1.69
Daily Volume273K
All-time high145.95
1y analyst estimate27.63
Beta2.02
EPS (TTM)-2.14
Dividend per share0.04
Ex-div date21 Sep 2018
Next earnings date6 Nov 2023

Downside potential

Loading...
Downside potential data
ACETS&P500
Current price drop from All-time high-98.84%-6.74%
Highest price drop-98.86%-56.47%
Date of highest drop25 Aug 20239 Mar 2009
Avg drop from high-78.47%-11.49%
Avg time to new high157 days13 days
Max time to new high1395 days1805 days
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
June 1, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
May 9, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACET (Adicet Bio Inc) company logo
Marketcap
72.59M
Marketcap category
Small-cap
Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
Employees
132
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
The following slide deck was published by Adicet Bio, Inc.
March 29, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
March 15, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
All eyes are on Adicet Bio as a pivotal study is launched into its cell therapeutics. Read more to see why Adicet stands out from the CAR-T crowd.
February 7, 2023
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
December 12, 2022
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
December 9, 2022
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
November 8, 2022
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
October 17, 2022
The following slide deck was published by Adicet Bio, Inc.
August 12, 2022
Get the latest news and real-time alerts from Adicet Bio, Inc. (ACET) stock at Seeking Alpha.
August 10, 2022
Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate.
July 22, 2022
The following slide deck was published by Adicet Bio, Inc.
July 1, 2022
The following slide deck was published by Adicet Bio, Inc.
June 10, 2022
iO Charts is a Seeking Alpha partnerNext page